In brief: Ambri; QIC; Solbec; IDT
Monday, 13 December, 2004
Sydney-based biosensor developer Ambri (ASX:ABI) has made chief financial officer Jeff Carter redundant, citing a drive to redirect resources towards its biosensor platform. Ambri's current financial controller, Phillip Camilleri, will assume the role of company secretary, and take over responsibility of all financial matters.
The Queensland Investment Corporation (QIC) has become a substantial shareholder in Melbourne's Prima Biomed (ASX:PPR), with a holding of 5.6 per cent.
Perth-based biotech Solbec Pharmaceuticals (ASX:SBP) has signed up the Adelaide-based Institute of Drug Technology (ASX:IDT) to manufacture its Coramsine compound to FDA standard for Phase II clinical trials. The compound is currently being tested as a therapeutic for cancer and psoriasis.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
